EUVIMEDEUVIMED entdecken
Crossref

Anti-PEG Single-Chain Variable-Fragment Antibody-Assisted In Vivo Process Decoding of PEGylated Nanomedicines

Feng Pan, Qingyuan Xu, Kaisong Tian, Gan Luo, Yawen Qi, Yinyu Ma, Tianlei Ying, Jun Qian iD, Zhenlin Yang, Changyou Zhan iD, Kuan Jiang iD

ACS Nano · 11.08.2026 · 20 (31) · 22215-22232

DOI: 10.1021/acsnano.6c09408 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Nano, online erschienen am 25.07.2026. Verfasst von Feng Pan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Basic Medical Sciences and Department of Pharmacy, Shanghai Pudong Hospital, Fudan University, Shanghai200032, …. Hauptthemen laut MEDLINE: Polyethylene Glycols, Doxorubicin, Single-Chain Antibodies, Nanomedicine. Die Arbeit nennt 47 Literaturangaben. Gefördert von: Ministry of Science and Technology of the People's Republic of China, Science and Technology Commission of Shanghai Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clinical translation of nanomedicines is greatly hindered by insufficient understanding of their in vivo process, yet a key challenge lies in quantifying the encapsulated versus free drug forms in tissues and cells. Herein, we present a facile, versatile anti-PEG single-chain variable-fragment antibody (PEG-scFv)-based method enabling quantitative measurement of both forms in various biofluids (e.g., interstitial fluid, cytoplasm). By this method, we map the in vivo process of PEGylated liposomal doxorubicin (sLip/Dox) at unprecedented resolution. In the bloodstream, doxorubicin remains largely encapsulated in liposomes (>99%). In liver as the main organ for drug elimination, less drug was distributed in the interstitium (>80% encapsulated) but more in liver cells (mainly in Kupffer cells) released in a time-dependent manner, accompanying doxorubicin transferred to hepatocytes most in free form by 12 h postinjection. After extravasation into tumors, there was a limited access of sLip/Dox to tumor cells, confining most of the drug in the interstitium mainly being encapsulated (more than 75%), and the internalized fraction underwent a gradual release process in both tumor-associated macrophages and tumor cells. These findings revealed that for sLip/Dox, which primarily underwent drug release intracellularly, cellular internalization rates could be the key factor in determining its in vivo performance. Given widespread PEGylation on developing nanomedicines and the cost-effectiveness of scFv production, PEG-scFv offers a broadly applicable tool for dissecting in vivo processes of nanomedicines to establish dose–effect relationships like small-molecule drugs, further to guide rational nanotherapeutic design.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polyethylene GlycolsDoxorubicinSingle-Chain AntibodiesNanomedicineAnimalsMiceHumansTissue DistributionLiver

Stichwörter der Autor:innen

Kupffer cellsPEGylated nanomedicinedose−effect relationshipin vivo processnanobio-interaction

Substanzen

Polyethylene GlycolsDoxorubicinSingle-Chain Antibodiesliposomal doxorubicin

Autor:innen und Institutionen

  • Department of Pharmacology, School of Basic Medical Sciences and Department of Pharmacy, Shanghai Pudong Hospital, Fudan University, Shanghai200032, P. R. China.
  • School of Pharmaceutical Sciences, Fudan University and Key Laboratory of Smart Drug Delivery (Fudan University), Ministry of Education, Shanghai201203, P. R. China.
  • Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai200032, P. R. China.
  • Shanghai Key Laboratory of Lung Inflammation and Injury, Shanghai200032, P. R. China.
  • Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Science, Fudan University, Shanghai200032, P. R. China.
  • Shanghai Institute of Infectious Disease and Biosecurity, Shanghai200032, P. R. China.

ORCID-Profile: Jun Qian, Changyou Zhan, Kuan Jiang

Förderung

  • Ministry of Science and Technology of the People's Republic of China
  • Science and Technology Commission of Shanghai Municipality

Zitieren

APA

Pan, F., Xu, Q., Tian, K., Luo, G., Qi, Y., Ma, Y., Ying, T., Qian, J., Yang, Z., Zhan, C., & Jiang, K. (2026). Anti-PEG Single-Chain Variable-Fragment Antibody-Assisted In Vivo Process Decoding of PEGylated Nanomedicines. ACS Nano, 20(31), 22215-22232. https://doi.org/10.1021/acsnano.6c09408

Vancouver

Pan F, Xu Q, Tian K, Luo G, Qi Y, Ma Y, et al. Anti-PEG Single-Chain Variable-Fragment Antibody-Assisted In Vivo Process Decoding of PEGylated Nanomedicines. ACS Nano. 2026;20(31):22215-22232. doi:10.1021/acsnano.6c09408

BibTeX
@article{Pan2026,
  author = {Pan, Feng and Xu, Qingyuan and Tian, Kaisong and Luo, Gan and Qi, Yawen and Ma, Yinyu and Ying, Tianlei and Qian, Jun and Yang, Zhenlin and Zhan, Changyou and Jiang, Kuan},
  title = {Anti-PEG Single-Chain Variable-Fragment Antibody-Assisted In Vivo Process Decoding of PEGylated Nanomedicines},
  journal = {ACS Nano},
  year = {2026},
  volume = {20},
  number = {31},
  pages = {22215--22232},
  doi = {10.1021/acsnano.6c09408}
}
Kostenlos starten →